Amgen Inc.

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: AMGN-1 Category:

Description

Amgen Inc: An Analysis Of The Pipeline Progress and Development!

 

Amgen’s Fourth Quarter 2023 Financial Results Conference Call highlighted several strategic moves and positive outcomes for the biotechnology company. This past year, the company acquired Horizon Therapeutics, which foundationalized a new branch contributing to its growth. Also, 18 of Amgen’s medicines reached record annual sales, including Repatha, Prolia, EVENITY, TEZSPIRE, BLINCYTO, KRYSTEXXA, and UPLIZNA.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!